Nutra MED Packaging Inc

Nutra-Med Packaging Inc, established in 1999 by Mahesh Gupta, is a contract packaging company specializing in the pharmaceutical, health & wellness, and medical device sectors. Headquartered in Whippany, New Jersey, the company offers a comprehensive suite of packaging services, including bottling, blistering, and secondary packaging such as cartoning, shrink sleeving, heat seal carding, kitting, and retail pallet pack-out. These services cater to both prescription (Rx) and over-the-counter (OTC) products, as well as dietary supplements.

In February 2022, GenNx360 Capital Partners, a New York City-based private equity firm, invested in Nutra-Med Packaging. This partnership aims to support the company's growth initiatives and operational execution. As of January 2026, Hany Salama assumed the role of Chief Executive Officer, bringing over 20 years of global experience in healthcare, biopharma, consumer health, and life sciences.

Nutra-Med Packaging operates four centrally located facilities within a half-mile radius in New Jersey: Whippany, Hanover, and East Hanover. These facilities collectively encompass over 215,000 square feet, with 50,000 square feet dedicated to production and 123,000 square feet for warehousing of finished goods, bulk, and components. This strategic proximity enhances operational efficiency and facilitates rapid service delivery.

Nutra-Med Packaging Inc functions as a contract packaging provider within the United States pharmaceutical supply chain. By offering specialized packaging services, the company supports pharmaceutical manufacturers in delivering their products to the market efficiently and in compliance with regulatory standards. This role is crucial for ensuring that pharmaceutical products are presented in a manner that maintains their integrity and meets consumer expectations.

Nutra-Med Packaging's sourcing from India is highly concentrated, with 97.7% of its imports originating from PAR Formulations Private Limited. This significant dependency on a single supplier may pose risks related to supply chain disruptions, quality control, and pricing negotiations. The limited number of shipments (47) and the dominance of a single supplier suggest a strategic choice to maintain consistency and quality, but it also indicates potential vulnerabilities in the supply chain.

The resilience of Nutra-Med Packaging's Indian supply chain appears limited due to the heavy reliance on a single supplier, PAR Formulations Private Limited. The absence of backup suppliers and the narrow range of imported formulations (7 unique products) suggest a lack of diversification. This concentration could lead to challenges in mitigating risks associated with supplier disruptions, regulatory changes, or quality issues. Additionally, the exposure to specific shipping routes and the regulatory compliance status of the sole supplier further impact the supply chain's robustness.

Nutra-Med Packaging's concentrated sourcing strategy may offer benefits such as streamlined operations and stronger supplier relationships. However, it also exposes the company to significant risks, including supply chain disruptions and limited flexibility in product offerings. For Indian exporters, this presents an opportunity to diversify their client base by offering alternative products or services that align with Nutra-Med's needs, potentially reducing the company's dependency on a single supplier.

In the United States, the Food and Drug Administration (FDA) is the primary regulatory authority overseeing the importation of pharmaceutical products. Key legislation governing these imports includes the Federal Food, Drug, and Cosmetic Act (FDCA), which sets standards for drug safety, efficacy, and labeling. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating and approving new drugs, including those imported from foreign markets.

Importers of pharmaceutical products into the United States must ensure that their foreign suppliers are registered with the FDA and that their facilities comply with Good Manufacturing Practice (GMP) standards. The FDA recognizes various GMP certifications, including those from the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers are also required to obtain an import license and ensure that all imported drugs are properly labeled and meet FDA standards.

Imported pharmaceutical products must adhere to FDA labeling requirements, which include accurate and truthful information in English. This encompasses details such as drug identity, strength, dosage form, and directions for use. Batch testing and stability studies are essential to ensure product quality and efficacy. Additionally, serialization mandates require that each saleable unit of prescription drugs be assigned a unique serial number to enhance traceability and prevent counterfeit products from entering the supply chain.

Between 2024 and 2026, the FDA has implemented several policy changes affecting the importation of pharmaceutical products from India. These include stricter enforcement of GMP compliance, enhanced scrutiny of drug labeling and packaging, and the introduction of new serialization requirements to combat counterfeit drugs. Importers must stay informed about these changes to ensure continued compliance and avoid potential disruptions in their supply chains.

Nutra-Med Packaging's focus on respiratory and corticosteroid products aligns with market demands for treatments addressing respiratory conditions and inflammation. The significant import values of methylprednisolone, prednisolone, and prednisone indicate a strategic emphasis on these therapeutic areas, likely driven by consistent demand and the company's expertise in packaging such formulations.

Nutra-Med Packaging's sourcing strategy is heavily concentrated on generic drug formulations, particularly corticosteroids. The company's reliance on a single supplier in India suggests a preference for established relationships and consistent product quality. However, this approach may limit flexibility and expose the company to risks associated with supply chain disruptions or regulatory changes affecting the sole supplier.

Based on its product mix, Nutra-Med Packaging serves a segment of the United States market that includes retail pharmacies, hospitals, and government tenders. The company's focus on packaging services for both prescription and over-the-counter products positions it to meet the needs of various stakeholders in the pharmaceutical supply chain, ensuring that medications are delivered to end-users in optimal condition.

There is a realistic opportunity for new Indian suppliers to engage with Nutra-Med Packaging by offering alternative products or services that align with the company's packaging capabilities and market focus. Diversifying Nutra-Med's supplier base could mitigate risks associated with single-source dependency and enhance supply chain resilience. Identifying gaps in Nutra-Med's current sourcing, such as the need for additional product formulations or packaging solutions, presents avenues for collaboration.

Indian exporters seeking to supply Nutra-Med Packaging and the U.S. market must ensure that their manufacturing facilities are registered with the FDA and comply with recognized GMP standards, such as EU GMP, WHO GMP, or PIC/S. Additionally, products must meet FDA labeling requirements, including accurate and truthful information in English. Compliance with serialization mandates is also essential to facilitate traceability and prevent counterfeit products.

Indian exporters should initiate engagement with Nutra-Med Packaging by demonstrating their compliance with FDA regulations and GMP standards. Participating in industry trade shows, establishing direct communication channels, and presenting product portfolios that align with Nutra-Med's packaging capabilities can facilitate relationship building. Understanding the regulatory filing process and timelines for FDA approvals is crucial for effective collaboration. Patience and persistence are key, as establishing new supplier relationships can be a time-consuming process.